MS Briefs

Comboridies Adversely Impact Cognition in MS


 

Key clinical point: Better management and treatment of diabetes and anxiety in MS patients may help improve cognition.

Major finding: Of 111 patients with relapsing remitting MS (majority were women with a mean age of 50 years), 22.7% had hypertension, 10.8% had diabetes, 9.9% had depression, and 9.9% had anxiety disorders.

Study details: Patients completed a psychiatric interview, a comorbidity questionnaire, and cognitive testing. Scores were converted to age-, sex-, and education-adjusted z-scores. Links between diabetes and hypertension and the cognitive z-scores were evaluated.

Disclosures: Authors disclosed receiving research support from various organizations. One author has conducted clinical trials for Biogen Idec and Rouche. Another has served as a consultant for several pharmaceutical companies, and has also received research grants and served on speaker’s bureaus for the industry.

Citation: Marrie, RA, et al.. Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018.

Recommended Reading

FDA approves diroximel fumarate for relapsing MS
ICYMI Multiple Sclerosis
Interview with Clyde E. Markowitz, MD on switching therapies during MS treatment
ICYMI Multiple Sclerosis
Algorithms help identify RRMS patients
ICYMI Multiple Sclerosis
Impact of polypharmacy in RRMS
ICYMI Multiple Sclerosis
Cost-effective treatment for relapsing MS patients
ICYMI Multiple Sclerosis
MS-related disability may be decreasing
ICYMI Multiple Sclerosis
From DMTs to Secondary Progressive MS
ICYMI Multiple Sclerosis
Time to Disability Milestones in MS Is Lengthening
ICYMI Multiple Sclerosis
Late-onset MS is often more severe than earlier-onset MS
ICYMI Multiple Sclerosis
Is FOXP3 Gene Polymorphism a Risk for MS?
ICYMI Multiple Sclerosis